Journal of Cancer Prevention

eISSN 2288-3657
pISSN 2288-3649

Comparison of baseline characteristics of the 78 patients with non-squamous non-small cell lung cancer according to the tumor mutation burden status
Baseline characteristics Total TMB status χ2 P-value
TMB-H (n = 38) TMB-L (n = 40)
Age (yr) NA 0.617
Median (range) 63 (21-78) 63 (25-78) 63 (21-77)
Sex 0.216 0.642
Male 37 (47.4) 17 (44.7) 20 (50.0)
Female 41 (52.6) 21 (55.3) 20 (50.0)
ECOG PS score 0.004 0.952
0 49 (62.8) 24 (63.2) 25 (62.5)
1-2 29 (37.2) 14 (36.8) 15 (37.5)
Smoking history 0.000 0.991
Yes 41 (52.5) 20 (52.6) 21 (52.5)
No 37 (47.4) 18 (47.4) 19 (47.5)
Histological type
Adenocarcinoma 71 (91.0) 35 (92.1) 36 (90.0) 0.106 0.745
Other type 7 (9.0) 3 (7.9) 4 (10.0)
Pathological staging 0.773 0.379
II 51 (65.4) 23 (60.5) 28 (70.0)
IIIa 27 (34.6) 15 (39.5) 12 (30.0)
EGFR gene mutation status 0.470 0.493
Positive 38 (48.7) 17 (44.7) 21 (52.5)
Negative 40 (51.3) 21 (55.3) 19 (47.5)
Surgical resection type 0.889 0.346
Lobectomy 61 (78.2) 28 (73.7) 33 (82.5)
Pneumonectomy 17 (21.8) 10 (26.3) 7 (17.5)
Adjuvant chemotherapy regimens 0.008 0.931
Cisplatin-based regimen 53 (67.9) 26 (68.4) 27 (67.5)
Carboplatin-based regimen 25 (32.1) 12 (31.6) 13 (32.5)
Adjuvant chemotherapy regimens 0.248 0.883
Platinum combined with pemetrexed 41 (52.6) 20 (52.6) 21 (52.5)
Platinum combined with docetaxel 19 (24.4) 10 (26.3) 9 (22.5)
Platinum combined with vinorelbine 18 (23.1) 8 (21.1) 10 (25.0)
Cycles of adjuvant chemotherapy NA 0.621
Median (range) 3 (1-5) 3 (1-5) 3 (1-5)

Values are presented as number (%). TMB, tumor mutation burden; TMB-H, TMB the high level group; TMB-L, TMB the low level group; ECOG, eastern cooperative oncology group; PS, performance status; EGFR, epidermal growth factor receptor; NA, not available.

J Cancer Prev 2023;28:175~184 https://doi.org/10.15430/JCP.2023.28.4.175
© J Cancer Prev
© Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd